Effective Combination Chemotherapy with Bimonthly Docetaxel and Cisplatin with or without Hematopoietic Growth Factor Support in Patients with Advanced Gastroesophageal Cancer
Authors:
- Gabriela V. KornekGKGabriela V. Kornek
- Katharina SchmidKSKatharina Schmid
- Markus RadererMRMarkus Raderer
- Michael HejnaMHMichael Hejna
- Alfred LenauerALAlfred Lenauer
- Dieter DepischDDDieter Depisch
- Fritz LangFLFritz Lang
- Werner ScheithauerWSWerner Scheithauer
- 1 December 2003
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 65 (3) , 211-217
Abstract
Purpose: A phase II trial was performed to determine the antitumor efficacy and tolerance of combined docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. Patients and Methods: Thirty-seven patients with histologically confirmed metastatic gastroesophageal cancer were entered in this trial. Treatment consisted of 4-weekly courses of docetaxel 50 mg/m2 and cisplatin 50 mg/m2 both given on day 1 and 15. Depending on absolute neutrophil counts on the days of scheduled chemotherapeutic drug administration (1,000–2,000/µl), a 5-day course of human granulocyte colony-stimulating factor (G-CSF) 5 µg/kg/day was given subcutaneously; in addition, if hemoglobin was Results: The confirmed overall response rate (intent-to-treat) was 46%, including 4 complete responses (11%) and 13 partial responses (35%). Eleven patients (30%) had stable disease and 9 (24%) progressed while on treatment. The median time to response was 3 months, the median time to progression was 7 months and the median overall survival time was 11.5 months with 16 (43%) patients currently alive. Hematologic toxicity was common, though WHO grade 4 neutropenia occurred only in 3 patients. Nonhematologic adverse reaction were usually mild to moderate; grade 3 toxicities included alopecia in 5 patients (14%), infection in 1 (3%), neutrotoxicity in 2 (5%) and anaphylaxis in 1 patient. Conclusion: Our data suggest that the combination of docetaxel and cisplatin with or without G-CSF and/or erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal cancer.Keywords
This publication has 9 references indexed in Scilit:
- Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric CancerJournal of Clinical Oncology, 2002
- Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2002
- Neoadjuvant and Adjuvant Chemotherapy of Locally Advanced Stomach CancerOncology Research and Treatment, 2001
- A phase II study of paclitaxel, weekly, 24-hour continuous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerBritish Journal of Cancer, 2000
- Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinomaAnnals of Oncology, 2000
- Phase II Trial of the Combination of Paclitaxel and 5-Fluorouracil in the Treatment of Advanced Gastric CancerAmerican Journal of Clinical Oncology, 1999
- Implantable Vascular Access Systems: Experience in 1500 Patients with Totally Implanted Central Venous Port SystemsWorld Journal of Surgery, 1998
- Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnnals of Oncology, 1997
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961